| Literature DB >> 27540096 |
Alexandra Pollitt1, Dimitris Potoglou2, Sunil Patil3, Peter Burge3, Susan Guthrie3, Suzanne King3, Steven Wooding3, Steven Wooding3, Jonathan Grant1.
Abstract
OBJECTIVES: (1) To test the use of best-worst scaling (BWS) experiments in valuing different types of biomedical and health research impact, and (2) to explore how different types of research impact are valued by different stakeholder groups.Entities:
Keywords: HEALTH ECONOMICS; STATISTICS & RESEARCH METHODS
Mesh:
Year: 2016 PMID: 27540096 PMCID: PMC5013498 DOI: 10.1136/bmjopen-2015-010916
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Overview of methods.
Draft categorisation of impacts, developed from the existing literature
| Category | Knowledge production and research targeting | Capacity building | Innovative and economic impact | Health and health sector benefit | Policy and public services (other than health) | Public engagement, dissemination, culture and creativity |
|---|---|---|---|---|---|---|
| Types of impacts and measures of those impacts included in this category | Volume and quality measures | Esteem measures | New products and process developed | Impact on guidelines/policy/professional training or development in health | Changes to policy outside of health | Number and range of dissemination and outreach activities |
NHS, National Health Service.
Attributes and levels (domains and impacts) used in the surveys
| Level | ||||
|---|---|---|---|---|
| Domain | 1 | 2 | 3 | 4 |
| Knowledge (KNOW) | Research replicates the findings of others, helping to strengthen the evidence of how some things work (KNOW1). | Research results in a new finding, helping to focus subsequent research activities (KNOW2). | Research shows that something does not work, eliminating the need for further investigation (KNOW3). | Research reviews and combines previous findings, identifying areas of consistency and difference (KNOW4). |
| REF impact (IMPACT) | Research generates knowledge that is world leading (IMPACT1). | Research generates knowledge that is internationally excellent but which falls short of the highest standards of excellence (IMPACT2). | Research generates knowledge that is recognised internationally (IMPACT3). | Research generates knowledge that is recognised nationally (IMPACT4). |
| Training (TRAIN) | Research trains young people who go on to work in industry as scientists (TRAIN1). | Research trains young people, who become researchers and lecturers in universities (TRAIN2). | Research trains doctors and nurses who also become researchers (TRAIN3). | Research trains young researchers who go on to work outside of science (eg, in business, in the civil service, as teachers) (TRAIN4). |
| Jobs (JOBS) | Research helps create new jobs in the university (JOBS1). | Research helps create new jobs in one town (JOBS2). | Research helps create new jobs in one region (JOBS3). | Research helps create new jobs across the UK (JOBS4). |
| Private funding (PVT) | Research contributes to a follow-up study in the UK being funded by a company (PVT1). | Research contributes to an existing UK research facility being partly funded by a company (PVT2). | Research contributes to a new UK research facility being set up by a company (PVT3). | Research contributes to a company deciding to move a major part of its operations to the UK (PVT4). |
| Life expectancy (QOLY) | Research contributes to the development of a treatment that would increase life expectancy by 3 months for the 10% of adults living with a common disease in the UK (QOLYR, QOLYRC). | Research contributes to the development of a treatment that would increase life expectancy by 6 months for the 10% of adults living with a common disease in the UK (QOLYR, QOLYRC). | Research contributes to the development of a treatment that would increase life expectancy by 1 year for the 10% of adults living with a common disease in the UK (QOLYR, QOLYRC). | Research contributes to the development of a treatment that would increase life expectancy by 3 years for the 10% of adults living with a common disease in the UK (QOLYR, QOLYRC). |
| Cost of care (COST) | Research contributes to care being provided more cheaply without any change in quality (COST1). | Research contributes to better care being provided at the same cost (COST2). | Research contributes to better care being provided at a higher cost (COST3). | Research contributes to more choice of care at the same quality and cost (COST4). |
| Dissemination (DISS) | Researchers talk in schools about their research (DISS1). | Researchers give interviews to the media about their research (DISS2). | Researchers give public lectures about their research (DISS3). | Researchers consult the public to help set research priorities (DISS4). |
REF, Research Excellence Framework.
Figure 2Example of best–worst scaling tasks.
Response summary for both surveys
| Researchers | General population | |
|---|---|---|
| Response rate | 31% | NA |
| Number of total responses | 1431 | 1113 |
| Number of complete responses (no missing data) | 966 | 1000 |
| Number of respondents with missing data | 465 | 113* |
| Number of respondents who completed at least one BWS scaling task | 1171 | 1000 |
| Survey completion rate | 68% | 90% |
| Observation exclusion criteria | ||
| Completed 8 BWS tasks under 5 min | 2 (0.2% of complete responses) | 170 (2.2%) |
| Did not understand most of BWS tasks | 37 (4% of complete responses) | 102 (10%) |
| Unable to make comparisons in most BWS | 146 (15% of complete responses) | 129 (13%) |
BWS, best–worst scaling; NA, not available.
General public model and researchers estimates
| Model group | General public | Researchers | |
|---|---|---|---|
| Description of research impact | Coefficient name | Coefficient† (95% CI) | Coefficient† (95% CI) |
| Research contributes to care being provided more cheaply without any change in quality. | COST1 | 4.582 (4.318 to 4.847) | 4.087 (3.851 to 4.324) |
| Research contributes to better care being provided at the same cost. | COST2 | 4.613 (4.349 to 4.876) | 4.632 (4.397 to 4.868) |
| Research contributes to better care being provided at a higher cost. | COST3 | 2.278 (2.029 to 2.527) | 2.557 (2.322 to 2.793) |
| Research contributes to more choice of care at the same quality and cost. | COST4 | 4.349 (4.087 to 4.611) | 3.168 (2.922 to 3.415) |
| Researchers talk in schools about their research. | DISS1 | 0.884 (0.668 to 1.1) | 1.085 (0.866 to 1.304) |
| Researchers give interviews to the media about their research. | DISS2 | 0 NA | 0 NA |
| Researchers give public lectures about their research. | DISS3 | 0.308 (0.097 to 0.519) | 0.937 (0.719 to 1.155) |
| Researchers consult the public to help set research priorities. | DISS4 | 1.917 (1.677 to 2.157) | 1.813 (1.576 to 2.05) |
| Research generates knowledge that is world leading. | IMPACT1 | 3.572 (3.305 to 3.839) | 3.487 (3.248 to 3.726) |
| Research generates knowledge that is internationally excellent but which falls short of the highest standards of excellence. | IMPACT2 | 4.385 (4.12 to 4.649) | 5.04 (4.804 to 5.277) |
| Research generates knowledge that is recognised internationally. | IMPACT3 | 3.817 (3.549 to 4.085) | 3.868 (3.631 to 4.106) |
| Research generates knowledge that is recognised nationally. | IMPACT4 | 3.729 (3.466 to 3.992) | 3.662 (3.424 to 3.899) |
| Research helps create a small number of new jobs in the university. | JOBS1 | 1.646 (1.419 to 1.874) | 1.265 (1.048 to 1.482) |
| Research helps create a small number of new jobs in one town. | JOBS2 | 1.489 (1.263 to 1.715) | 0.154* (−0.049 to 0.356) |
| Research helps create a substantial number of new jobs in one region. | JOBS3 | 1.832 (1.594 to 2.069) | 1.153 (0.939 to 1.367) |
| Research helps create a substantial number of new jobs across the UK. | JOBS4 | 3.345 (3.081 to 3.61) | 3.269 (3.036 to 3.503) |
| Research replicates the work of others, helping to strengthen the evidence of how some things work. | KNOW1 | 4.554 (4.287 to 4.822) | 5.512 (5.274 to 5.75) |
| Research results in a new finding, helping to focus subsequent research activities. | KNOW2 | 2.618 (2.365 to 2.871) | 3.418 ( 3.176 to 3.66) |
| Research shows that something does not work, eliminating the need for further investigation. | KNOW3 | 4.036 (3.766 to 4.305) | 5.086 (4.847 to 5.325) |
| Research reviews and combines previous findings, identifying areas of consistency and difference. | KNOW4 | 3.521 (3.256 to 3.787) | 2.876 (2.626 to 3.127) |
| Research contributes to a follow-up study in the UK being funded by a company. | PVT1 | 2.805 (2.553 to 3.056) | 1.052 (0.839 to 1.265) |
| Research contributes to an existing UK research facility being partly funded by a company. | PVT2 | 2.794 (2.544 to 3.045) | 1.07 (0.854 to 1.286) |
| Research contributes to a new UK research facility being set up by a company. | PVT3 | 2.796 (2.542 to 3.05) | 1.699 (1.476 to 1.922) |
| Research contributes to a company deciding to move a major part of its operations to the UK. | PVT4 | 2.968 (2.707 to 3.229) | 2.097 (1.859 to 2.335) |
| Research trains young researchers who become researchers in industry. | TRAIN1 | 3.713 (3.453 to 3.974) | 3.081 (2.848 to 3.314) |
| Research trains young researchers who become university professors. | TRAIN2 | 3.368 (3.109 to 3.626) | 3.768 (3.535 to 4.002) |
| Research trains young researchers who become doctors and nurses. | TRAIN3 | 3.775 (3.511 to 4.038) | 2.832 (2.595 to 3.069) |
| Research trains young researchers who go on to work outside of science (eg, in business, in the civil service, as teachers). | TRAIN4 | 2.449 (2.193 to 2.704) | 2.094 (1.857 to 2.332) |
| Value of change in 1 year on life expectancy of 10% of adults living with a common chronic disease in the UK | QOLYR | 0.408 (0.363 to 0.453) | 0.532 (0.493 to 0.57) |
| Intercept on life expectancy | QOLYRC | 4.399 (4.139 to 4.658) | 3.959 (3.727 to 4.191) |
| Impact statement position—bottom most | Bottom | 0.128 (0.032 to 0.224) | 0.395 (0.296 to 0.494) |
| Impact statement position—second from the top | Top2 | 0.145 (0.078 to 0.213) | NA |
| Impact statement position—top most | Top | 0.192 (0.125 to 0.258) | 0.171 (0.113 to 0.228) |
| Scale for second worst preference | Scale4 | 0.468 (0.437 to 0.499) | 0.365 (0.342 to 0.388) |
| Scale for second best preference | Scale3 | 0.62 (0.583 to 0.656) | 0.577 (0.551 to 0.602) |
| Scale for worst preference | Scale2 | 0.593 (0.557 to 0.629) | 0.489 (0.462 to 0.517) |
| Scale for best preference(fixed to one) | Scale1 | 1 NA | 1 NA |
*p=0.132.
†p<0.05 for all estimated model coefficients except where explicitly specified.
NA, not available.
Figure 3Preferences for different types of research impact, expressed as additional years of life expectancy (AYLE) for 10% of adults living with a common chronic disease in the UK. Note that the shaded (non-transparent) boxes illustrate impacts that are statistically different between the general public and researchers.